GUIDELINES FOR SUBMITTING APPLICATION FOR …
2 table of contents i. abbreviations ii. foreword iii. introduction iv. glossary 1. application form for registration and marketing of a medicine in the sadc region 1 2.
Download GUIDELINES FOR SUBMITTING APPLICATION FOR …
Information
Domain:
Source:
Link to this page:
Documents from same domain
ICH HARMONISED TRIPARTITE GUIDELINE
www.ich.orgGOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting
Final Concept Paper Q12: Technical and Regulatory ...
www.ich.orgFINAL Q12 Concept Paper Endorsed: 9 September 2014 -3- product lifecycle management. To date, the main emphasis has been on the implementation of
Q7 Implementation Working Group ICH Q7 …
www.ich.orgInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Secretariat, Chemin des Mines 9, P.O. Box 195, 1211 Geneva 20, Switzerland
GUIDELINE FOR GOOD CLINICAL PRACTICE
www.ich.orgGUIDELINE FOR GOOD CLINICAL PRACTICE INTRODUCTION Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the
ICH HARMONISED GUIDELINE
www.ich.orgE6(R1) Document History First Codification History Date New Codification November 2005 E6 Approval by the Steering Committee under Step 2 and release for public consultation.
ICH HARMONISED GUIDELINE - ICH Official web …
www.ich.orginternational conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ich harmonised guideline guideline for elemental impurities
![[ICH E2F] [EXAMPLE DSUR – PHASE III …](/cache/preview/1/3/5/f/e/1/c/f/thumb-135fe1cf2cdb82799c462ad0ea089c48.jpg)
[ICH E2F] [EXAMPLE DSUR – PHASE III …
www.ich.orgfictional document for illustrative purposes only document date: 5 october 2010 [ich e2f] [example dsur – phase iii investigational drug] zb3579
ADDENDUM TO ICH E11: CLINICAL INVESTIGATION …
www.ich.org3 ICH HARMONISED GUIDELINE ADDENDUM TO ICH E11: CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION E11 (R1) ICH Consensus Guideline Released for Adoption on 18 August 2017, at Step 4 of the ICH
M4Q Implementation Working Group Questions & …
www.ich.org1. Introduction This document is intended to provide additional guidance for the preparation of an application file in the CTD-Q format (see section 2: General Issues).
I ADDENDUM TO ICH E6(R1 ... - ICH Official web site
www.ich.orgi ICH HARMONISED GUIDELINE INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE ICH E6(R2) Draft ICH Consensus Guideline Released for Consultation on 11 June 2015, at Step 2 of the ICH Process
Related documents
Annex 9 Guidelines on packaging for …
apps.who.int121 The complexity of packaging materials and the highly technological nature of medicinal products is such that manufacturers are …
LABELLING OF MEDICAL GAS CONTAINERS - …
asiaiga.orgAIGA 88/14 2 Pharmacopoeia – An authoritative published book (or list) of medicinal drugs, describing their preparation including specification and analytical methods, and their use. PIL (Patient Information Leaflet) – A leaflet supplied by the manufacturer of a licensed medicine to the patient.
Draft reflection paper on the use of methyl- and ...
www.ema.europa.eumedicinal products is one of the priorities among excipients under revision. 36 Parabens are currently listed in the guideline on excipients in the label and package leaflet of medicinal
Questions and answers on wheat starch containing …
www.ema.europa.euQuestions and answers on wheat starch containing gluten as an excipient in the context of the revision of the guideline on ‘Excipients in the label and package leaflet of
Notes Key - The Feingold Diet
www.feingold.orgADI Acceptable Daily Intake. An estimate of the amount of a substance in food or drinking-water, expressed on a body-weight basis, that can be ingested daily over a lifetime without appreciable risk
Public Assessment Report Decentralised Procedure …
www.mhra.gov.ukPAR Lorazepam 1 & 2.5mg Tablets UK/H/3130, 4683-5/001-2/DC 3 TABLE OF CONTENTS Module 1: Information about initial procedure Page 4 Module 2: Summary of Product Characteristics Page 5
Labelling Requirements for Investigational …
dgra.deLabelling Requirements for Investigational Medicinal Products in Multinational Clinical Trials: Bureaucratic Cost Driver or Added Value? Wissenschaftliche Prüfungsarbeit